Drug intelligence / Profile preview

SQ9

Development stage: Preclinical
Lead developer: Multiverse Pharma
Modality: Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

SQ9 is a preclinical-stage drug candidate being developed by Multiverse Pharma. It is engineered using the company's proprietary Fc-heterodimerization platform, a technology designed to enable the production of stable multispecific antibodies or Fc-fusion proteins by promoting the correct assembly of heterodimeric heavy chains. While the specific molecular targets and primary disease indications for SQ9 have not yet been publicly identified, the asset represents an application of Multiverse Pharma's protein engineering capabilities in the development of next-generation biologics.

Beyond the preview

Go deeper on SQ9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SQ9.

Explore the full profile